Vγ2 x PD-L1, a Bispecific Antibody Targeting Both the Vγ2 TCR and PD-L1, Improves the Anti-Tumor Response of Vγ2Vδ2 T Cell.

导出 LinkOut

翻译打印收藏纠错

第一作者： Rui,Yang

第一单位： Department of Early Discovery and Research, Wuhan YZY Biopharma Co., Ltd, Wuhan, China.

作者： Rui,Yang ^[1] ; Qing,He ^[1] ; Hui,Zhou ^[1] ; Cheng,Gong ^[1] ; Xing,Wang ^[1] ; Xingpan,Song ^[1] ; Fang,Luo ^[1] ; Yang,Lei ^[1] ; Qian,Ni ^[1] ; Zili,Wang ^[1] ; Shasha,Xu ^[1] ; Yan,Xue ^[1] ; Man,Zhang ^[1] ; Haimei,Wen ^[1] ; Lijuan,Fang ^[1] ; Liang,Zeng ^[1] ; Yongxiang,Yan ^[1] ; Jian,Shi ^[1] ; Jing,Zhang ^[1] ; Jizu,Yi ^[1] ; Pengfei,Zhou ^[1]

作者单位： Department of Early Discovery and Research, Wuhan YZY Biopharma Co., Ltd, Wuhan, China. ^[1]

关键词 PD-L1 Vγ2Vδ2 T cell [Vγ2 x PD-L1]adoptive transfer immunotherapy

主题词抗体, 双特异性(Antibodies, Bispecific);HEK293细胞(HEK293 Cells);人类(Humans);肿瘤(Neoplasms);受体, 抗原, T细胞(Receptors, Antigen, T-Cell);T淋巴细胞(T-Lymphocytes)

DOI 10.3389/fimmu.2022.923969

PMID 35784353

发布时间 2022-07-20

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交